Commission
-
European Commission approves SUTENT
The European Commission has approved Pfizer 's SUTENT (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults. Experience with SUTENT as ini…
Commission | 23 February 2011
-
Novartis Granted Pediatric Indication for Hypertension Treatment
The European Commission (EC) has granted Diovan (valsartan) a pediatric indication for the treatment of hypertension in children and adolescents 6-18 years of age. Following the Commission's decision, the pediatric indication needs to be implemented …
Commission | 13 May 2010
-
Veolia to Commission Water Treatment Plant in Singapore
Veolia Water will design and commission a wastewater treatment plant to treat effluents from a pharmaceutical drug manufacturing site in Singapore. The plant consists of two key technologies, an AnoxKaldnes Moving Bed Bio Reactor (MBBR) biologica…
Commission | 23 December 2009
-
AstraZeneca: Diabetes Drug Receives Marketing Authorization In Europe
AstraZeneca and Bristol-Myers Squibb Company have announced that the European Commission has granted marketing authorisation for Onglyza (saxagliptin) in the 27 countries of the European Union. The drug is indicated as a once-daily 5 mg oral tabl…
Commission | 08 October 2009
-
Watson Pharmaceuticals and Arrow Group Receive FTC Second Request
Watson Pharmaceuticals has received a request for additional information from the Federal Trade Commission (FTC) in connection with the company’s pending acquisition of privately held Arrow Group. The information request was issued under notifi…
Commission | 13 August 2009
-
AstraZeneca Receives Marketing Authorization for Lung Cancer Drug
AstraZeneca has announced that the European Commission has granted marketing authorization for an oral anti-cancer drug. Iressa is used for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activatin…
Commission | 01 August 2009
